L30, Collins Place
35 Collins Street
Melbourne, VIC 3000
Australia
61 3 9827 8999
https://www.PercheronTx.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA | CEO, MD & Director | 9.77k | N/A | 1973 |
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. | CFO & Joint Company Secretary | 160.28k | N/A | 1959 |
Dr. Anthony Filippis | Chief Operating Officer | 329.82k | N/A | N/A |
Ms. Alicia Mellors | Joint Company Secretary | N/A | N/A | N/A |
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. The company was incorporated in 2000 and is based in Melbourne, Australia.
PERCHERON FPO [PER]’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.